Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 54, Issue 8 (Aug 2016)

Issues

SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer

Ioanna Balgkouranidou
  • Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece
  • Department of Medical Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Maria Chimonidou
  • Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Georgia Milaki
  • Department of Medical Oncology, University Hospital of Heraklion, Medical School, University of Crete, Heraklion, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Emily Tsaroucha
  • 8th Department of Pulmonary Diseases, “Sotiria” General Hospital for Chest Diseases, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Stylianos Kakolyris
  • Department of Medical Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Vasilis Georgoulias
  • Department of Medical Oncology, University Hospital of Heraklion, Medical School, University of Crete, Heraklion, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Evi Lianidou
  • Corresponding author
  • Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2016-01-07 | DOI: https://doi.org/10.1515/cclm-2015-0776

Abstract

Background: SOX17 belongs to the high-mobility group-box transcription factor superfamily and down-regulates the Wnt pathway. The aim of our study was to evaluate the prognostic significance of SOX17 promoter methylation in circulating tumor DNA (ctDNA) in plasma of non-small cell lung cancer (NSCLC) patients.

Methods: We examined the methylation status of SOX17 promoter in 57 operable NSCLC primary tumors and paired adjacent non-cancerous tissues and in ctDNA isolated from 48 corresponding plasma samples as well as in plasma from 74 patients with advanced NSCLC and 49 healthy individuals. SOX17 promoter methylation was examined by Methylation Specific PCR (MSP).

Results: In operable NSCLC, SOX17 promoter was fully methylated in primary tumors (57/57, 100%), and in corresponding ctDNA (27/48, 56.2%) while it was detected in only 1/49 (2.0%) healthy individuals. In advanced NSCLC, SOX17 promoter was methylated in ctDNA in 27/74 (36.4%) patients and OS was significantly different in favor of patients with non-methylated SOX17 promoter (p=0.012). Multivariate analysis revealed that SOX17 promoter methylation in ctDNA was an independent prognostic factor associated with OS in patients with advanced but not operable NSCLC.

Conclusions: Our results show that SOX17 promoter is highly methylated in primary tumors and in corresponding plasma samples both in operable and advanced NSCLC. In the advanced setting, SOX17 promoter methylation in plasma ctDNA has a statistical significant influence on NSCLC patient’s survival time. Detection of SOX17 promoter methylation in plasma provides prognostic information and merits to be further evaluated as a circulating tumor biomarker in patients with operable and advanced NSCLC.

Keywords: cell free DNA; circulating tumor DNA; DNA methylation; methylation specific PCR; non-small cell lung cancer; prognostic significance; SOX17

References

  • 1.

    Janssen-Heijnen ML, van Erning FN, De Ruysscher DK, Coebergh JW, Groen HJ. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol 2015;5:902–7.Google Scholar

  • 2.

    Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol 2014;32:973–82.Google Scholar

  • 3.

    Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, et al. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2014;9:1618–24.Google Scholar

  • 4.

    Carter BW, Glisson BS, Truong MT, Erasmus JJ. Small cell lung carcinoma: staging, imaging, and treatment considerations. Radiographics 2014;34:1707–21.Web of ScienceGoogle Scholar

  • 5.

    Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121–27.Web of ScienceGoogle Scholar

  • 6.

    Stella GM, Scabini R, Inghilleri S, Cemmi F, Corso S, Pozzi E, et al. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. J Cancer Res Clin Oncol 2013;139:1327–35.Google Scholar

  • 7.

    Balgkouranidou I, Liloglou T, Lianidou ES. Lung cancer epigenetics: emerging biomarkers. Biomark Med 2013;7:49–58.Web of ScienceGoogle Scholar

  • 8.

    Lou-Qian Z, Rong Y, Ming L, Xin Y, Feng J, Lin X. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis. PLoS One 2013;8:e54970.Web of ScienceGoogle Scholar

  • 9.

    Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 2004;10:6119–25.Google Scholar

  • 10.

    Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598–607.Web of ScienceGoogle Scholar

  • 11.

    Chiu RW, Lo YM. Clinical applications of maternal plasma fetal DNA analysis: translating the fruits of 15 years of research. Clin Chem Lab Med 2013;51:197–204.Google Scholar

  • 12.

    Marzese DM, Hirose H, Hoon DS. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn 2013;13:827–44.Web of ScienceGoogle Scholar

  • 13.

    Aung KL, Board RE, Ellison G, Donald E, Ward T, Clack G, et al. Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J 2010;4:11–21.Google Scholar

  • 14.

    Nie K, Jia Y, Zhang X. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumour Biol 2015;36:7–19.Google Scholar

  • 15.

    Balgkouranidou I, Chimonidou M, Milaki G, Tsarouxa EG, Kakolyris S, Welch DR, et al. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Br J Cancer 2014;110:2054–62.Web of ScienceGoogle Scholar

  • 16.

    Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426–37.Web of ScienceGoogle Scholar

  • 17.

    Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Manegold C, et al. Prognostic significance of RASSF1A promoter methylation on survival in non small cell lung cancer patients treated with gemcitabine. Lung Cancer 2007;56:115–23.Web of ScienceGoogle Scholar

  • 18.

    Ponomaryova AA, Rykova EY, Cherdyntseva NV, Skvortsova TE, Dobrodeev AY, Zav’yalov AA, et al. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer 2013;81:397–403.Google Scholar

  • 19.

    Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Münsterberg A, et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 1990;346:245–50.Google Scholar

  • 20.

    Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, et al. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 2007;27:7802–15.Web of ScienceGoogle Scholar

  • 21.

    Zhang W, Glöckner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 2008;68:2764–72.Google Scholar

  • 22.

    Fu DY, Wang ZM, Li-Chen, Wang BL, Shen ZZ, Huang W, et al. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat 2010;119:601–12.Google Scholar

  • 23.

    Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 2011;57:1169–77.Web of ScienceGoogle Scholar

  • 24.

    Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou ES. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem 2013;59:270–9.Web of ScienceGoogle Scholar

  • 25.

    Kroupis C, Christopoulos K, Devetzoglou M, Tsiagas I, Lianidou ES. Asymmetric real-time PCR detection of BRCA1 mutation by melting curve analysis in the LightCycler. Clin Chim Acta 2008;390:141–4.Web of ScienceGoogle Scholar

  • 26.

    Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, et al. A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples. Clin Chim Acta 2015;444:303–9.Google Scholar

  • 27.

    Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci 2014;51:160–71.Google Scholar

  • 28.

    Faugeroux V, Pailler E, Auger N, Taylor M, Farace F. Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer. Front Oncol 2014;4:281.Google Scholar

  • 29.

    Marzese DM, Hoon DS. Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn 2015;15:647–64.Google Scholar

  • 30.

    Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, et al. Cell Free DNA Working Group. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst 2014;106:dju214.Google Scholar

  • 31.

    Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat 2014;146:163–74.Web of ScienceGoogle Scholar

  • 32.

    Ilie M, Hofman V, Long E, Bordone O, Selva E, Washetine K, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med 2014;2:107.Google Scholar

  • 33.

    Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345–53.Web of ScienceGoogle Scholar

  • 34.

    Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014;110:55–62.Web of ScienceGoogle Scholar

  • 35.

    Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentes AA, et al. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clin Chem Lab Med 2013;51:1505–10.Web of ScienceGoogle Scholar

  • 36.

    Du YC, Oshima H, Oguma K, Kitamura T, Itadani H, Fujimura T, et al. Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology 2009;137:1346–57.Web of ScienceGoogle Scholar

  • 37.

    Li Z, Guo X, Wu Y, Li S, Yan J, Peng L, et al. Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients. Breast Cancer Res Treat 2015;149:767–79.Web of ScienceGoogle Scholar

  • 38.

    Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 2014;106:djt356.Google Scholar

About the article

Corresponding author: Prof. Evi Lianidou, Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, 15771, Greece, Phone: +30 210 7274319, Fax: +30 210 7274750, E-mail:


Received: 2015-08-10

Accepted: 2015-11-01

Published Online: 2016-01-07

Published in Print: 2016-08-01


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2015-0776.

Export Citation

©2016 by De Gruyter. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
José Luis García-Giménez, Salvador Mena-Mollá, Jesús Beltrán-García, and Fabian Sanchis-Gomar
Clinical Chemistry and Laboratory Medicine (CCLM), 2017, Volume 55, Number 10
[2]
Xiao Han, Junyun Wang, and Yingli Sun
Genomics, Proteomics & Bioinformatics, 2017, Volume 15, Number 2, Page 59
[3]
Yan Lu, Shulin/SL Li, Shiguo/SG Zhu, Yabin/YB Gong, Jun/J Shi, and Ling/ L Xu
Biological Procedures Online, 2017, Volume 19, Number 1
[4]
Zibo Li, Jianfu Heng, Jinhua Yan, Xinwu Guo, Lili Tang, Ming Chen, Limin Peng, Yepeng Wu, Shouman Wang, Zhi Xiao, Zhongping Deng, Lizhong Dai, and Jun Wang
Breast Cancer Research and Treatment, 2016, Volume 160, Number 2, Page 371
[5]
Marco Tomasetti, Monica Amati, Jiri Neuzil, and Lory Santarelli
Lung Cancer, 2017, Volume 107, Page 65

Comments (0)

Please log in or register to comment.
Log in